- Procaterol Hydrochloride Inhalation Solution
Procaterol hydrochloride is a β2 agonist with high selectivity for β2 adrenergic receptors in bronchial smooth muscle, and is used for the treatment of bronchial asthma, chronic bronchitis, and chronic obstructive pulmonary disease, and only oral formulations and dry powder inhaler formulations are commercially available. The nebulized inhalation solution developed by us follows a direct drug delivery approach using the respiratory tract and lungs as target organs, which is ideal for clinical treatment of respiratory diseases. It features the advantages of rapid onset of action, good efficacy, few systemic adverse reactions, and no need for deliberate patient cooperation. It thus can provide a more effective and safe treatment solution for patients with asthma and chronic obstructive pulmonary disease.
Product introduction
Generic name: Procaterol Hydrochloride Inhalation Solution
Strength: 0.5 mL:50 μg (calculated as C16H22N2O3·HCl·½H2O)
Indications: It is primarily intended to relieve symptoms related to airflow restriction of the following diseases: bronchial asthma, chronic bronchitis, emphysema.
Package: 5 pcs/bag, 2 bags/box.
Approval No.: Guo. Yao. Zhun. Zi. No. H20233837
Product advantages
It achieves rapid onset of efficacy by directly targeting the lesion. The test shows that the bronchiectasis effect can be observed within 5 minutes after inhaling procaterol hydrochloride, and the onset time by inhalation is shorter than that by oral administration.
The effect is direct and efficient, with high concentration of target organ drug delivery and better efficacy.
It features smaller drug load, reduced systemic adverse effects and higher safety.
It is easy to use and has better compliance than oral or intravenous dosage forms.
Product parameters
Generic name：Procaterol Hydrochloride Inhalation Solution
Strength：0.5 mL:50 μg (calculated as C16H22N2O3·HCl·½H2O)
Dosage form: Solution for inhalation
Unit： 5 pcs/bag, 2 bags/box.
Approval No.Guo. Yao. Zhun. Zi. No. H20233837
Marketing authorization holder：Nanjing Aureole Pharmaceutical Co., Ltd.